Rituximab for the first-line treatment of stage III-IV follicular lymphoma

  • Technology appraisal guidance
  • TA243
  • Published: 
Download guidance (PDF)

Changes after publication

February 2014: implementation section updated to clarify that rituximab is recommended as an option for treating stage III-IV follicular lymphoma.

July 2012: minor maintenance

June 2012: minor maintenance